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By letter of 29 May 1984, the President of the Council of the European 
Communities requested the European Parliament to deliver an opinion, pursuant 
to Article 235 of the EEC Treaty, on the proposal from the Commission of the 
European Communities to the Council for a decision adopting a multiannual 
research action programme of the European Economic Community in the field of 
qiotechnology (1985-1989). 
On 11 September 1984, the President of the European Parliament referred 
this proposal to the Committee on Energy, Research and Technology as the 
~ommittee responsible and to the Committee on Budgets, the Committee on 
Economic and Monetary Affairs and Industrial Policy, the Committee on 
Agriculture, Fisheries and Food and the Committee on the Environment, Public 
Health and Consumer Protection for opinionso 
The Committee on Legal Affairs and Citizens~ Rights was also asked for an 
opinion on December 1984. 
At its meeting of 11 September 1984P the Committee on Energy, Research and 
Technology appointed Mrs VIEHOFF rapporteur. 
The committee considered the Commission's proposal and the draft report at 
its meetings of 20 September, 16 October and 28 November 1984. 
At the last meeting, the committee decided unanimously to recommend to 
Parliament that it approve the Commission's proposal with the following 
amendments .. 
The Commisson stated before the committee that it was prepared to accept 
Amendments Nos. 1-10. 
The committee then adopted unanimously the motion for a resolution as a 
w'hole. 
The following took part in the vote: Mr PONIATOWSKI, chairman: Mr SALZER 
ahd Mr ADAM, vice-chairmen, Mrs VIEHOFF, rapporteur; Mr CIANCAGLINI, Mr FICH 
(deputizing for Mr WEST), Mr GRIFFITHS (deputizing for Mrs LIENEMANN), 
Mr KILBY (deputizing for Mr MOLLER), Mr LINKOHR, Mr MEGAHY (deputizing for 
Mrs LIZIN), Mr METTEN (deputizing for Mr GLEZOS), Mr MUNCH, Mr PETERS 
(deputizing for Mr SMITH), Mr RINSCHE, Mr STAES, Mr TOKSVIG and Mr TURNER. 
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The opinions of the Committee on Budgets, the Committee on Agriculture, 
Fisheries and Food, the Committee on the Environment, Public Health and 
Consumer Protection and the Committee on Legal Affairs and Citizens' Rights 
are attached. 
The report was tabled on 30 November 1984. 
The deadline for tabling amendments to this report will be indicated in 
the draft agenda for the part-session at which it will be debated. 
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The Committee on Energy, Research and Technology hereby submits to the 
European Parliament the following amendments to the Commission's proposal and 
a motion for a resolution together with explanatory statement: 
I. Proposal from the Commission of the European Communities to the Council 
for a decision adopting a multiannual research action programme of the 
European Economic Community in the field of biotechnology (1985-1989) 
Text proposed by the Commission 
of the European Communities 
Amendments tabled by the Committee 
on Energy, Research and Technology 
Preamble, recitals 
1-10 unchanged 
Preamble 
THE COUNCIL OF THE EUROPEAN 
COMMUNITIES 
Having regard 
Cllllil00(118Clffl08i)8 
(unchanged) 
Whereas a Community research action 
programme is necessary for the 
development of biotechnology in the 
Community and, particularly for: 
- the establishment of new methods 
for the synthesis of compounds 
with high added value, 
WGC2)1335E -6-
Amendment No. 1 
Preamble, recital 11 to read as 
follows 
(amend or add indents>: 
Preamble 
Whereas a Community research action 
programme is necessary for the 
development of biotechnology in the 
Community and, particularly for: 
- the establishment of new methods 
for the synthesis of compounds 
with high added value and for 
lowering production costs, 
PE 91.447/fin. 
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Text proposed by the Commission 
of the European Communities 
= more efficient land use through 
the design of new crops which can 
provide important feedstocks for 
the European industries, 
= acceptability of the products of 
modern biotechnology through the 
use of new testing methods which 
render possible a more efficient 
and less costly evaluation of 
toxicity and biological activity 
= new approaches in the detection& 
prevention and treatment of 
costly diseases&' 
- protection of health and environment 
against risks which may be associated 
to new developments in modern 
biotechnology 11 
- Whereas it is necessary to monitor 
developments in biotechnologyp with 
a view to assessing their strategic 
significance for Europe, and to 
promote effective concertation 
between the Community and its Member 
States in matters affecting the 
development of biotechnology; 
WG(2)1335E 
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Amendments tabled by the Committee 
on Energy, Research and Technology 
- unchanged 
- application of biotechnology to 
environmental protection~ 
= unchanged 
= replacement of animal experiments 
with tests on cell cultures, 
new approaches in the det~cti9n~ 
prevention and treatment~ 
diseases 
= protection of health and environ= 
ment against risks which may be 
associated with new developments 
in and the application of 
biotechnology 
PE 91 .. 447/fin.,, 
of the European Communities 
WGC2)1335E 
on Energy, Research and Technology 
Amendment No .. 2 
Preamblee twelfth recital, to be 
expanded as follows: 
such monitoring is also needed to 
ensure that problems of a social, 
ethical and ecological nature, 
inherent in the application of this 
technology, may be recognized in 
good time and their adverse 
consequences prevented; 
Rest of preamble 
unchanged 
Article 1(1) and (2) 
unchanged 
Amendment No. 3 
ADD a new sub-paragraph 3: 
(3) Encouragement and priority shall 
be given to contracts bringing 
together the technological 
resources of firms and 
institutions from different 
Member States, where possible. 
Article 2 
unchanged 
-8- PE 91.447/fin. 
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Text proposed by the Commission 
of the European Communities 
Article 3 
The Commission will report to the 
Council and the European Parliament 
at the end of the third year of the 
programme and will propose, where 
appropriate, any amendments necessary. 
These amendments may lead to a 
revision of the programme in the 
course of the fourth year in 
accordance with the appropriate 
procedures. 
-----------'-··-·-~-------
Amendments tabled by the Committee 
on Energy, Research and Technology 
Amendment No. 4 
Article 3 to read as follows: 
Article 3 
At the beginning of the third year 
the Commission shall submit to the 
Council an interim report on the 
results of the programme. On the 
basis of this report, the programme 
shall be evaluated before the end of 
the third yeare This evaluation 
shall be carried out by experts not 
involved in the Committee referred 
to in Article 5 and who have 
themselves not received any 
appropriations under the research 
programme. A report on this 
evaluation shall be sent to the 
Council and to ·the European 
Parliament. 
This evaluation may lead to the 
submission by the Commission of a 
proposal for a revision of the 
programme in accordance with the 
appropriate procedures. 
Articles 4 - 6 
unchanged 
WGC2)1335E -9- PE 91.447/fin. 
of the European Communities 
Article 7 
(1) In accordance with Article 228 
of the Treaty the Community may 
conclude Agreements with non-Member 
States participating in European 
Cooperation in the field of 
Scientific and Technical research 
(COST) with a view to ensuring 
cooperation between the Community 
concerted action projects referred 
to in the Annex and the relevant 
programmes of such States. 
(2) The Commission is hereby 
authorized to negotiate the 
Agreements referred to in paragraph 1e 
ANNEX 
on Energy, Research and Technology 
Amendment No. 5 
Article 7, paragraph 1, to read as 
follows: 
Article 7 
(1) In accordance with Article 228 of 
the Treaty the Community may conclude 
Agreements with non-Member States 
participating in European Cooperation 
in the field of Scientific and 
Technical research (COST) or 
international organizations with a 
view to ensuring cooperation between 
the Community concerted action 
projects referred to in the Annex and 
the relevant programmes of such 
States or international 
organizations. 
(2) unchanged 
ACTION I - Sub-programme 1 
- Bio-informatics 
Third indent 
- Computer modelling of biological 
structures and systems 
WG(2)1335E 
Amendment No. 6 
Add to the third indent: 
- Computer modelling of biological 
structures, systems and processes. 
-10- PE 91.447/fin. 
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Text proposed by the Commission 
of the European Communities 
ACTION I, Sub-programme 2, 
2nd paragraph 
- Development and evaluation of bio-
reactors <and particularly those 
which are multienzymatic, multi-
. phas i c or co-factor requiring) 
for industrial applications, 
depollution and detoxification .. 
- unchanged 
"" '"' ..... _.._ ... _~ -- . 
Amendments tabled by the Committee 
on Energy, Research and Technology 
Amendment No .. 7 
Subprogramme 2, 2nd paragraph 
'Enzyme engineering•, add to the 1st 
indent: 
ACTION I, Sub-programme 2, 
2nd paragraph 
- Development and evaluation of bio-
reactors <and particularly those 
which are multienzymatic, multi-
phasic or co-factor requiring) for 
industrial and medical applications 
depollution and detoxification. 
- unchanged 
Sub-programme 2 
3rd paragraph 
'Genetic Engineering' 
1st to 3rd indents 
unchanged 
3rd paragraph 
- Genetic engineering 
WG(2}1335E 
Amendment No. 8 
Add the following indent: 
3rd paragraph 
- Genetic engineering 
- Production of vaccines, proteins 
and hormones for human medicine. 
-11- PE 91.447/fin. 
of the European Communities on Energy, Research and Technology 
Sub-programme 2 
4th and 5th paragraph 
1st to 4th indents 
unchanged 
5th paragraph, 5th indent 
- Study of cell biology applied to 
the prevention, detection and 
treatment of a few selected diseases 
which are particularly important 
from a socio-economic point of view. 
Amendment No. 9 
5th indent to read as follows: 
5th paragraph, 5th indent 
- Study of cell biology applied to 
the prevention, detection and 
treatment of a few selected 
diseases. 
Rest of Sub-paragraph 2 
unchanged 
ACTION II CONCERTATION 
First to seventh indents 
unchanged 
8t h indent 
disseminating knowledge 
and increasing public awareness 
of the nature and potential of 
biotechnology and the Life sciences, 
to raise the quality of public 
debate; 
WG(2)1335E 
Amendment No. 10 
8th indent 
.!.r!!e..!:.t the following in the 8th 
indent: 
- disseminating knowledge and 
increasing public awareness of 
-12-
the nature, potential and risks of 
biotechnology and the Life 
sciences, to raise the quality of 
pub Li c debate; 
PE 91.447/fin. 
A 
MOTION FOR A RESOLUTION 
closing the procedure for consultation of the European Parliament on the 
proposal from the Commission of the European Communities to the Council for a 
decision adopting a multiannual research action programme of the European 
Economic Community in the field of biot~chnology (1985-1989) 
The European Parliament, 
- having regard to the proposal from the Commission to the Council 1, 
- having been consulted by the Council pursuant to Article 235 of the EEC 
Treaty (Doc. 1-335/84), 
- having regard to its resolution of 20 November 1980 on a multiannual 
Community programme of research and development in biomolecular engineering 
<indirect action 1981-1985) 2, 
- having regard to the report of the Committee on Energy, Research and 
Technology and the opinions of the Committee on Budgets, Committee on 
Economic and Monetary Affairs and Industrial Policy, Committee on 
Agriculture, Fisheries and Food, Committee on the Environment, Public Health 
and Consumer Protection and of the Committee on legal Affairs and Citizens' 
Rights (Doc. 2-1144/84), 
- having regard to the result of the vote on the Commission's proposal, 
A. recognizing the widespread application possibilities of biotechnology and 
its possible contribution to new economic activities, but bearing also in 
mind the far-reaching consequences of the use of biotechnology, 
B. noting that many aspects of genetic engineering may lead to dangers for 
human society and for the environment, 
1 OJ Noa C 182, 9.7.84, Pa 7 
2 
OJ No~ C 327, 15.12.80, P~ 38 (Doc. 1-521/80, SCHMID report) 
WG(2)1335E 
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Cw recalling the prom1s1ng results of the Biomolecular Research and Training 
Programme and the growing willingness among the best European laboratories 
to cooperate within this framework that can also be considered as an 
important building block, 
Do aware that R & D funding by governments for biotechnology in Europe lags 
behind the USA, 
Ee noting the fragmented market, the duplication of R & D efforts in the 
Member States, and therefore the need of a concertation unit to coordinate 
national and European research, training and information on biotechnology, 
Fs aware of the European competitive edge in several sectors and the 
promising chances for a European biotechnology industry, 
1~ Stresses the political importance and economic necessity for a European 
Biotechnology Action Programme; 
2~ Calls, however, at the same time, for an adequate European biotechnology 
assessment programme - drawn up in close collaboration with national 
assessment programmes - which covers all political, economic, legal, 
ethical and environmental aspects and involves the participation of a 
broad spectrum of the social groups concerned; 
3o Welcomes the institution of a programme as a means not only to stimulate 
research, but also to bring together European expertise at present 
fragmented by Community internal frontiers, and by the lack of sufficient 
contracts between firms and universities in different Member States; 
4~ Stresses the need to encourage small and medium-sized enterprises to 
participate in the implementation of the programme; 
5~ Requests the Commission to stimulate research projects having regard to 
work already in progress in USA and Japan so as to create an indigenous 
European biotechnological capability based on international cooperation 
where this is appropriate and on independent actions where this is 
desirable; 
WG(2)1335E 
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6. Stresses the need for a stimulation programme for the dow0$tream, 
. ·1 
processing j_ndustey and. for ~.i_oinolecular soft~art,. nqt onit with 0 t.he 
' ... ~, ~·; ~· . .: ~/ . ',. . ' ' ... - ... ... ': .. :· '~) , ' '.'~· :,- '. ,,.. '·~-~ 
larger firms whi c·11 hav.e access to ri°sk capi.Ul, but also with innovative 
. ; . ;: ,:t;.,~,~- ,' ' .. ~~~-~~ ,.; !... ' f! • ., • • . 'I .• . "· .; ' 
small and medium-sized firms, and for th-is p1.u"po-se. :!t.t~eS;ses :t,ha netd for 
the adoption of the Community scheme to provide risk capital in the form 
of innovation loans to smal.l and medium sized firms H c1.Y.td f_o.r .. by the 
» ~ ,t } _l • ' ; ';:": ' .'~: "~;~~ >• " -, • : . • ~- ;· . • '!\) , \ J 
Commission and Parliam:f!'tlt in the draft budget 1,985, line ~1l .. 
Recog_nizes t~e postit,i v~- ;·_ieffe~t ~- of cooper~tlqrt wi,t h -~:~R,~J Jnd. ot~er 
' ~ . . 1 ~ , , ~ 
Community inf.orrnattonld~el«fflentation progr._~·,; 
..... ~,'-· \ .p1:, _:,,: ~\!~/;..t-- ;:+·•:~··_,,<~~,- . .· •. ,;-,, 
8. Urges measures to stem the European brain drain., in particular to the USA, 
by improving sc ient ifi c cooperation and th" exchange of scie:nt hts in. the 
:,,·,, .1 !•• ,- \ : !~~.,.._l.-,cr,· - •· :.;. ':· ,,. • 1 • 
Community and by em:ouraging research by ,European industrr;, · 
.. ., ; ·,.. .... ,:- ' ,, . . ... ' . ~. 
9.. Stresses the necessity of harmonization of p,attnt law to prevent unfair 
:, "'1 ·~ :_J . •, '~ ·~ 
comp.etition by ensuring that biotechnological innovations a.re treated 
harmoniously by the legal systems of the European Community; 
,. 
10. Underlines the .. need to ~armonhe safety guid~._l;ines in al L_ Me'{lber StaUs 
and d~,mands ~h~t. in, case of big differenc~s b~tween. na.tionat sde.ty 
guidelines ·for all experiments, Laboratory trials 1n9! pro~ction 
~·.{ 1 i ~ i'. ~··. -· · .:. .. · • - - · 
processes, the most far-reaching guideline.I wiU be- folle>~·i . 
11 .. Calls therefore. on the C~:n,_,_~ission to make proposa.Ls as.so.on lS,.poJsible in 
• .. i<' • 
the context of Act icm J:V for common safet~. P~,,,utions, patt.icularly for 
DNS recombinatioQs; 
. . ~ ' .. ,!~ 
12 .. Stresses the ma)0r impact biotechnology can have on agriculture, and thus 
urges for. a~ urgf:nt e>ttensi_on of, Cre)training hcHities and . 
on-the-job-training to anticipate .the e~p,cted growing outflow in 
; ' ' ~ I,\ . , . ;;._ ·._ I,' "•·:. • ' 
agriculture and the agro-food industry; 
13. Demands extensive research on a restructuring of th~ .. a,griculture policy of 
the ~omtftunit;:. (ne~ pric_es ~nd market re~i.m,e~4- ,~e.g. sta·rch .J~ ·.Sugar and irY 
the f~ture_also ~°.~ C?:t.her p~ducts); · · 
t ~ ·l 
WG(2) 1335E : . 
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14. Calls on the Commission to harmonize programme sections 2.2m2.4., 2a2.2.5. 
and 2.4 of the biotechnology research programme with Section 2b of the 
COST research action on the effects of processing and marketing on the 
quality and nutritional value of foodstuffs and in particulaf to 
investigate in this context the toxicological aspects of which no account 
was taken in the COST research action; 
15. Stresses the pressing need for an adequate policy for the regions most 
affected through the application of biotechnology; 
16. Recognizes the possible positive effects of biotechnology for the Third 
World; 
17~ Is aware, however, that the more likely negative effects necessitate 
protecting measures and guidelines to prevent the Third World countries 
being used as testing grounds, and stresses the need for international 
agreements on this; 
18. Demands that scientists from Third World countries be given easier access 
to training facilities in the Community; 
19. Calls upon the Commission to cooperate closely with the International 
Centers for Genetic Engineering and Biotechnology (ICGEB) of UNIDO in 
Trieste and in India; 
20~ Calls on the Commission to involve the trade unions in the implementation 
of this programme and, in particular, in the work of the Consultative 
Management and Coordination Committee (CMCC); 
21. Asks its Committee on Energy, Research and Technology to hold a hearing of 
experts on all biotechnology related questions; 
22. C3lls on the C:m,mission to adopt, on the basis of Article 149, second 
paragraph, of the EEC Treaty, the amendments whi eh it has tabled to the 
Commission's proposal; 
23. Instructs its President to forward to the Council and Commission, as 
Parliament's opinion? the Commission 1 s pr~posal as voted by Parliament and 
the corresponding resolution~ 
WG (2) 1335E PE 91.447/fin. 
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I .. INTRODUCTION 
8 
EXPLANATORY STATEMENT 
la Biotechnology has become one of the most rapidly developing fields 
of science and technology. Although biological processes and organisms 
have been used throughout history, modern scientifically based inter-
disciplinary biotechnology has developed only since the early 1940is .. 
As defined by the European Federation of Biotechnology: 
"Biotechnology ls the integrnted use of bi.ochemistry O microbiol-
ogy and engineering sciences to achieve the technological ap-
plication of the capabilities o( micro-organisms, cultured tissue 
cells and parts thereof .. "(l) 
2. In the past 10 years, drn1nc1tic new developments in the ability to 
select and manipulate genetic mc1te.r ial have cwnulated 1n a new techni-
que called 'genetic engineer.ing'eThe novel techniques used in biotech-
nology like Recombinant DNA technololUil Cell fusion, and Biopro-
cess technology, are extremely powerful because they allow a large 
c...~ount of control over biological systems.(2) Biotechnology could 
potentially affect any current industrial biological process or any 
process in which a biological catalyst could replace a chemical onee 
The potential appHcations are numerous .. Industrial applications will 
be found particularly in pha:rmaceuticals 0 animal and plant agricul-
ture p speciality chemicals and food additives, waste treatment and en-
vironmental areas, commodity chemicals and energy production, and 
hioelectronics.(3) 
3 .. The bior.echnology-related market is substantial since almost 40% of 
the products manufactured by the industrial countries are of 
biological origin. Recent estimates speak of a market of US$ 50-100 
billion for biotechnology by the year 2000. For recombinant DNA alone, 
the Gencx: Corporation (USA) predicts a volume of about US $ 40 
billion. ( 4) 
4. It seems that biotechnology can give an answer to some of the 
world's most pressing problems, such as disease, malnutrition, 
pollution and low-cost fuel, but expectations should not be exag-
gerated. Although exciting results of basic research emerge at an ever 
increasing rate, the prospects for the potential use of biotechnology 
will mainly depend on the economic, political, social, legal, and 
cultural conditions and risk assessment. These aspects have not got as 
much atter ion in the Commission's proposal as in other recent 
Commission papers. In this first r.eport some of these aspects will 
be described shortlyo In the final-report a more extensive elaboration 
of these and other aspects will follow. 
II.. THE POLITICAL IMPORTANCE AND ECONQMIC NEQCESSITY OF M EUROPEAN 
BIOTECHNOLOGY fB0f?.B4MME. 
5. According to the Commission 11strength in biotechnology is of stra-
tegic importance for the competitiveness of industry and agriculture, 
and for enhancing the quality of hum.an life and the natural environ-
ment."(5) Some theorists see biotechnology as a powerful tool for 
renewal and innovation of the bucio-economic base of contemporary 
society that provides an incentive and a direction for new capital ac-
17 PE 91 .. 447/f in .. 
cumulation needed to re-establish a phase of economic growth.{6) 
Others assume that biotechnology is altering certain aspects of the 
international division of labour through increased competition between 
the industries to which it is relevant (agro-food, petrochemicals, 
pharmaceuticals etce) and through increasing competition in domestic 
guropean markets as well as between Europe, the USA and Japane(7) 
Perhaps biotechnology could Also contribute t.o the easing of certain 
strategic constraints at world scal~p which weigh particularly upon 
countries in the Third World; basic health~ food production and 
storage 9 nutrition, energy and environmental problems.(8) 
. 6Q The importance of biotechnology as a ~y sector of future indus-
trial development is reflected in the numerous national governmental 
initiatives to promote biotechnology@(9) In some sense one can speak 
of a 1 biotechnology-race 1 o This can stimulate faster innovation~ 'but 
it can also lead to unnecessary secrecyp parallel R&D efforts and 
duplication~ wasting of money 9 and fragmented knowledgen Eventually it 
can lead to a situation in which one has to give the own market away 
to the strongest competitors, in particularly by signing joint 
ventures with American or Japanese firmso 
7. It is obvious that a serious danger lies in the growing dependancy 
of European firms that have concluded joint ventures or have obtained 
licencees from American firmso The extraterritorial jurisdiction of 
the U.ScA. makes it possible that American technologies and products 
(or parts for production) thot. are already i.n Europe, still remain 
under the American jurisdiction. This means that the length of the 
American trade arm is much longer and this can have severe repercus-
sions for the European counterpartso Furthermore 11 the American 
authorities can determine whether a high technology product (or parts 
of it) can be exported outside the USA. The list of products and parts 
that are non transferrable is growing ~for national security reasons'. 
Also the fact that Europeans are not always admitted anymore to 
congresses on high technology issues must be seen as a protectionist 
move of the U.S0 The blockage of information can be the more serious 
·the more dependent European companies are of their American 
counterparts .. 
Ba In a recent report of the Office of Science and Technology Policy 
for the US-Government it is stated that 1111 (,..,., )it has been a. matter of 
concern that the transfer of biotechnology abroad might jeopardize 
America's scientific and commercial leadership and national security 
interests~ This has engendered pressures for the implementation of 
government policies and regulations to control such transfer.n(lO) 
Although there is a common kno1s-J ledge base in biotechnology that can be 
, applied to the development and manufacture of military useful products 
(biological warefare-type agents) (ll)v the danger that other 
countries will be faster in commercial biotechnological appliances 
seems to be of more i.nteresto Export controls will be an attempt of 
the US Government to 0 balance national security and economic 
objectivese'°(l2) It is recommended to control better th~ channels for 
transferring those technologies, which range from exchanges and visits 
of scientists, trade ahowsi transfer of data bases 0 publications, 
licenses to patents, and industrial and military espionagea(l3) 
18 PE 91..447'/ fin., 
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9.. A joint European bfotechno~programme can provide a b~tter H'lter ... 
national coordination of efforts b1::t\.:Jeen ministries, disdpl itHe:f,. governments.., 
consumers, international bodi~sp university and industr)1" 9 • A concertation 
unit as proposed by the Co11mission seems to fut ti U these task~'! 
The . very promising results of the research and training progr&!}~e 
in bioaolt:euler engineering <19Si2-SO> 1 in which many of the ~st 
laboratort,es of· &.rope cooperat~., ~an bt seen H ~n import~t building 
for a mor&c\ eu,tent14ve ,bioteehuiolo;y progr,lffiffle.. There ist a ,-t~r9119 growing 
willingness a~ laborator-ies lind t>:icttdmologists to do ·international 
joint research an1i to.train foreign scie,ntists in tht fra~rk 
of the programme. Anot,tter re&son to suppo "t a European bictttfe.,no_logy 
pro1ra1m:11e - and ,· · dtis is perhaps even more ~rttc.iai- is that·· ft .~can 
sti~ula.~e . the cfeaUon of· a.n int~nml i~mropean murk~t en4 !iii· ... ~~on 
Kuropean legislation in biot(tdlnolo~y., in t~s context. a_l~o. the 
manets of Swcde·n, · Switzttrland, and Au~ria should b'= take« .tnto 
accc:»p,at as they UC participents of the European Molecular Biology 
Laboratorff: (EMBL) in Heide~-ber3 (DRU). The. 4imensio~ of . tt Eijropan 
market i's - a prere<nu'isite lor a competitive position of -;J.ndivi-al 
European f-inos. · 
10. The recent report of the Office of Technology AsseSSQ)W\t (OTA) of 
the Congress of the U.SoA., Commeirciel Biotechnology 8 an Igternation-
al Analysis, has made a thorough comparative analysis of the perspec-
tive's for co-.ercialisatton of the new btotechnologie8 by- the USA, 
Japan and four. ~uropean countriese the Federal Kepublic of .Germany, 
1h·ance,: du~ UK and Swit.zerlan.d .. (14) The main £9ncluaigos ~an be suaa-
dsed as follows: · 
· The J§A.. has· ·at present a competitive advancement in the commer-
cialisation of. biotechnology owing to a "ell-dt1:;1v~loped life 
science base, the ayail~bility of finane1tag for rl$k venture, and 
an entrepreneurial spirit .. Mo-re attention.should be dire&ted to 
research problC!IAs auoe1ated with scale-up of b1cprocee&Ns .for 
production . 
Jt'pat1 is likely to be the leadi.Ag competi:tor to the USA for two 
rea1.~·,r1s x a broad range of industrial · sectors have extenei ve 
expetience in bioprocess technology and the Japanese g.overl'Ullent 
has targeted biotechnology as a key technology oi the future, is 
funding its commercial development and coordinates uteractions 
among representatives from industry, universities and government. 
, The ·Kuro2 1ln countries (West-Germany, France. the UK amt. S~i.tzer-
land) are not moving as rapidly to ·commercialisation oJ · biot_ech-
nolo~y a.nd are not expected to be"."u strong competi~or.s a:a- the 
USA· and Japan. The European countries- generally do not proa.iote 
risk ·teking, either in industry or in government R()lide~: and 
they have few~r companies COB!leif'Cializing biotechnolo&J~ In 
ma.rke_ts for specific productF.i, ifftluding some pha.naaceuticale 11 
speeiality chemice.ls and aniul agriculture prod.ucts, some 
~utopean colll,panieS» \.n.U undou~otay be strong intemat,-onel _4;om-
petitorso 
11. The· CJrA Report only deals with four European countries. In a 
recent publication of the European Federation of Biotechnology. 
A Realistic View on Siotec.:.hno logy, ( September 1984) s portfolio chart 
· of biotechnology · is cooposed for 17 European countries. ( 15) A distinc-
tion is made betweP.n high-tech biotechnology (fermentation industry, 
pharmaceutical industry, fine chemicals, food/feed, biotechnological 
·equipment/plants and waste water treatment) and low-tech biotechnology 
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(food, alcoholic beverages, waste water treatmentg fermentation tech-
nology as ethanol, and biotechnological equipment). According to these 
data the European competive edges are fementation products\! phar-
maceuticals, alcoholic beverages and food/feed.. It seem.s that 
exporting countries with a broad representation in the high-tech 
biotechnologies are Denmark, Belgium~ West Germany, France, the 
Netherlands, Switzerland and the U. lC 
In the low-tech field of the more traditional biotechnologies the 
following countries with strung export positions are noted to have a 
broad coverage: Denmark, France, ItRly, the Netherlands, Switzerland 
and the U.Ke 
The total picture :indicates that in addition to West Germany, France, 
Italy and the U.K., the smaller countries which have a strong overall 
position are: Denmark, the Netherlands, Switzerland and Belgiume 
12. In several fields European companies have a leading position, par-
ticu!arly in pharmaceuticals and in the fermentation industry (en-
zymes, antibiotics)e(l6) However, some of the European pharmaceutical 
firms have transferred parts of their biotechnological research to the 
US.(17) This itself can be seen as an indicator of theweakness of the 
European marketo In a recent study by Frost snd Sullivan it is stated 
that Europe's position in international pharmaceutical markets is 
likely to deteriorate over the next five years because of the higher 
level of regulation of drug companies and prices by European govern-
ments.(18) The position in Europe contrasts sharply with the US where 
recent legislation will help to extmid patent life for drugsj thus 
protecting drug prices for the major drug innovators& 
Although the first industrial applications of biotechnology are expec-
ted to occur in pharmaceuticals, the Ccmununity should ghe more atten-
tion to the applications on the medium and long term in (animal) 
agriculture and speciality chemicsl§J An important reason for the 
l~tter priority is that the potential in the aecond cluster is much 
larger and that the pharmaceutical industry ie a strongly concen-
trstedg multinational industry with enough resources to fund research 
for its own purposes. The legal, regulatory and ethical aspects in the 
development of biotechnology for pharmaceuticals, however, should get 
· the full attention of the Communityo (See further paragraph VII~39). 
13., The lack of European competitiv~ness results from serious 
deficiencies and weaknesses affecting the entire training-research-
development-production-distrj.bution-network upon which modern tech-
nologies need to be baaedo They can be ascribed to scale and 
structural factors, which areo themselves@ the direct consequences of 
fragmentation into isolated national policiesa(l9) · 
140 Two other recent American studies arrived independently at the 
conclusion that Euro e's biotechnolo is la in behind the US and 
Japano(20) In one it is said that (eo• The US faces the stiffest 
challenge from Japan Q '~ And further: ~1( ~ •• )In general, the lack of 
· qualified scientist~ and engineers (particularly in process and puri-
fication technologies)~ inadequate induatry/w1iveraity cooperation~ 
and belated and insufficient R&D funding by industry and government, 
are probably the biggest barriers to commercial competitiveness in 
these countries~ wff In both reports Japan is seen as the most serious 
competitor to the Unlted States in biotechnology .. 
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15. The Commission of the European Communities claims that Europe has 
the scientific knowlegde, the industrial capacity and the agrarian 
basis to be "the world's n....rrt>er one" in biotechnology. (21) This opti-
mistic outlook is based on the following factors of strength:(22) 
a strong position in basic research 
a strong chemical and food industry 
a strong position in 'classical' biotechnology Q)rewery and dairy 
industries) 
increasing public spcmding (see paragraph IV) 
a strong agricultural btn1u; the 1:rnrplusses (sugar yeast., milk) 
can be used us i.ndUE:1tri.al inputs for biotechnologict1l proceases, 
- if the price level is Httractive enougll to the industry. (see 
also paragraph VII) 
IY .. GPYERNMENT FUNDS FOR BIGrECHNOLOGYo A COMPARISON BETWEEN THE 
UNITED STATES, JAPAN AND THE E!JROPEAN COMMUlUTY 
16. The multi- and interdisciplinary character of biotechnology and 
its wide spread applications make it particularly difficult to obtain 
a clear and quantitative picture of biotechnology R&D activity in the 
Member States and in the USA and Japan for comparison. The different 
figures reflect definitions varying from very narrow, to very 
'-- ~nsive, including agriculture and medical research, Therefore the 
fi.gures presented cannot give any more than 1a rough indication of the 
situJtion in 1982/83.(23) 
17. In the UNITill) STATES the main federal support for activities 
related to biotechnology is channelled through two sources: 
the National Science Foundation (NSF), which is the principal federal 
agency for the support of basic research across all fields of science, 
and the National Institutes of Health (NIH), which are responsible for 
basic research in medicine and health care, and are also responsible 
for the registration of federally funded research work on recombinant 
DNA.(24) The US Department of Agriculture (USDA) is also funding basic 
research related to agriculture, some of which involves projects and 
techniques which may be described as biotechnology; similarly the 
Department of Energy's studies of biomass-based energy sources involve 
basic biology and biotechnology. 
18. In fiscal year 1980~ the NIH supported 717 basic research projects 
involving reco ... ;binant DNA at a cost of $ 91.5 million. At the request 
of OTAj the NIH recently estimated what proportion of their budget 
might be classified as ''biotechnologyn: for FY 1982, approximately $ 
.380 m., versus$ 170 m .. in 1980 .. (25) "Biotechnology-relevant" research 
supported by the N8F in FY 1980 amounted to$ 66 m.(26) 
USDA's Competitive Grants Programme (1982: $ 16.Sm.) supports new 
research directions in plant biology. But here also, the 
biotechnology-relevant research is overshadowed by the total budget of 
the Agricultural Research Service($ 458m. proposed for 1984). The ARS 
budget itself forms only part of the Dept. of Agriculture's total R&D 
spending($ 839mQ estimated outlays in FY 1983), and including state 
programmes the total is over$ 1.5 billion a year.(27) 
19. Combining 
least$ 200 m. 
the figures suggests U.S .. federal expenditure of at 
p.a. in areas directly relevant to biotechnology. But 
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of equal or greater relevance to the country's strategic capability. 
are the much larger sums referred to which indicate that 10% of the total 
budgets of NIH~ NSF and USDA may be viewed as biotechnology-relevant41 
Hence one can arrive at the following estimate on this broader basis: 
NIH 
NSF 
USUA 
JJept. of 
ESTIMATION GOVERN?,11ENTAL k&D IN 'fH~ UNITED STATES 
10~ of $ 3. 7 bn/NIH t.:Stimate -
.IUotechnology resource Program 
(1980, careful estimate) 
10~ of ARS $ 426 m. (1982) ~ 
+ biotechnology elements of State 
Agricultural Experimenl Stations (50% 
federal, 50% State) 
Energy and other agencies 
TOTAL ESTIMATE 
$ 380 ndllion 
20 
66 
40 
30 
10-20 
$ 550 million 
200 In JAPAN, Government support for biotechnology dates from the 
beginning""'"oft"he 197U's@ The Science and Technology Agency initiated 
. the new government bioteclmology programmes by establishing a 
Committee for the Promotion of Life Science in 1973 .. (28) Support has 
increased steadily since then& Support in 1981 for Life Science in 
general is estimated at 1:1 minimum of¥ 50~000 million($ 195 m.) and 
if one considers only the more restricted areas which are currently 
referred to as l.dotechnology the support was of the order of ¥ 5 .600 
million (approximately$ 22 million) .. Government financial support has 
increased in 1982 with the announcement of the Ministry of 
International Trade and Induatryva (MIU) biotechnology national 
projects. These project:~ are the Biomass Development Project concerned 
with alcohol p:roducti.on (1980--1987 ~ total budget approximately $ 48 
m .. ) and the Next Generation Industries national project which has 
three biotechnology themes (1901-1991, total budget in biotechnology 
sector is approximately $ 116 m.)~(29) MIT! is coordinating its 
strategy through the _!)Jo-industry office and the 
Research Association for Biotechnol'Q&Y_., The work is mostly done by 
industry though paid for by the government. 
21c A more recent report quotes 76471 m. ¥ for government expenditure 
on biotechnology R&D in 1982P and 7~906 m. i (approximately$ 32.2m.) 
budgetted for 19839 apparently including all ministries and ageQcie~; 
if this omits the national projects cited above, the total must be 
well over$ 50 million p.a. for 19830(30) 
22. In the EUROPEAN COMM.UNITY we have to do with a fragmented market 
and with national initiatives of the Member States~ The last years 
show a growing tendency for joint Community R&D policy in 
biotechnologyu An example is the Biomolecular Engineering Programme 0 
which started in 1982 after several years of extensive consultations 
and reportso(31) Although the scope of the programme is very broad, the 
size of thi~ progr~me is mode~t: only 4 mioQ ECU p .. a .. ; however., the 
results a~e 1mpress1ve and can be seen as a first big step towards a 
European oiotechnology research programmeo The general objectives of the 
prog~amme are to promote and stimulate the development of new technologies 
leadrng to: 
a .. the manufactur~ of improved if.»il'lricultur8ll d '"'. · ..I\ • l ~ an u10-1nuustr1a products, 
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b. the determination of more efficient and safer production methods. 
Also in other related areas (eegQ agriculture research programme~ 
biotechnological research is doneo(32) 
:.l3a 'fhe efforts of the Member States on national level give the 
following rough indication:(33) 
SUMMAKY ESTIMAT!::S BY COUNTRY OF PUBLIC ~XPENDITURE 
QN JiltJfk!CNOLOGJ_)&D {11"1 1~. EqU}la )9j!2/198i) 
"BIO'rKQHNOLOG'l-
l}IO'!'~CHNOLOOY RWVAN'l:_ --
\~est-Gcr}nany 
(BMFT): llM 63 m .. (projects) + 20 m. 
(institutional support) =i DH 83 m .. : 
Alternatively, estimate 104 of 
medical, agro-food and life-
sciences research as "biotechnology 
relevant", i.eD "broad basisu: 
l•1runce 
----vf ioo filo on education and research 
in biotechnology in 1982: 
Alternatively, "broad basis": 
.ll!!ited Kingdom 
+Jaly 
h 28.8 m. (Research Councils, UGC, 
Dept. of Industry): 
Alternatively, "broad basis": 
CNM 5-year programmes on genetic 
engineering and biomedical/industry 
programme: 
Alternatively, "broad basis": 
Netherlands 
Hfl. 70m. for biotechnology 
programme ('82- 188) plus university 
research 10-20 Hfl. p.a.: about 25 
m. p.a .. : 
Alterna;ively: "broad basis": 
Belgium 
SSPS (molec.biol.etc.): FB 200 me 
paa.) plus ISRIA (100): at least FB 
300 m. p .. a.: 
Alternatively, "broad basis": 
Denmark, Greece, Ireland& Luxembourg:+ 
(US $ m.: 
23 -
36 
31 
46 
13 
10 
7 
3 
146 
---
130 
132 
84 
56 
34 
26 
14 
6 
355 
320 
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~4o For publicly supported R&D in biotechnology and related areas the 
following figures can give a rough indication for the position of the 
European Community, the USA and Japano 
European <..:ommuni ty: 146 million r.:t.:U on narrow basis~ up to 335 million 
ECU on broad basis ( $ 130 m., - $ 320 m. pa&.) 
United States: at least$ 200 million poac; up to$ 550 million 
p.ao on broad basise 
at least$ SU million p.u~ 
How tentative these figures are, they show at least that the R&D 
efforts of Europe in biotechnology are ~ess than in the US, but much 
higher than in Japan. However, the.!!.!.! of the R&D expenditures is 
not so important .. As we have learned from the Japanese efforts in 
microelectronics and computers the organization and coordination of 
research and development, as well as the interaction and 
training efforts are crucial. Some of these tasks can be fulfilled by 
a European concertation unit, as proposed by the Commission0 
It should be noted that the R&D expenditures of the governments 
are only a fraction of the R&D expenditures on biotechnology of the 
companies concerned. In 1982 the total industrial research expenditure 
in Japan was approximately$ 203 million and was rapidly rising.(34) 
Industrial funding in the US is probably at least 10 times that of 
federal expenditurep between$ 2 and 5.5 billion per annum.(35) For 
the European Com.munity no estimation was available a.s this first 
report was written~ 
y. THE IMPORTANCE OF SUPPORT INDUSTRIES FOR LARGE SCALE DEVELOPMENT 
QF BIOO.'§CHNQLOGY 
25e A major restraint on future large-scale development in the bio-
technological industry forms the limited range process operations 
that is available for the handling of fermentation broths and for 
subsequent processing~(36) The main conclusion of two recent FAST-
reports on "Technological forecasting for downstream processing in 
biotechnologi' is that there is a number of pressing needs for im-
proved performances and innovations in the downstream processing in-
dustry in Europe~ Downstream processing includes all stages subsequent 
to the fermentation stage of microbiological processeso Improvements 
are critical if the European biotechnology industry is to be competi-
tive~ and if biotechnology is to extend its range of application into 
bulk production via multi-stage processes or into products of mode-
rate value and scale of production~(37) A European effort is required 
to stimulate cooperation among users and suppliers, because Hthe range 
of problems and possibilities is too wide for any one organisation to 
pursue more than a fraction of those relevant to even one process 
sequence0n(38) In this respect the potential role of the Downstream 
Working Party of the European Federation of Biotechnology and their 
national counterparts is mentionedG 
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26. The European posit1on in downstream processing is less stron~ in 
specialised instrumentation and in consumables such as adsorbants and 
membranes. Much of the parent technology and manufacturing capacity is 
not European base<l.(3lJ) Consequently developments are not made availa-
ble for evaluation as early as tht~y would be in the parent countries 
and - although the delay in application is quite short (40)- this can 
lead to a further Blow down and a tl~pendens development of the Euro-
pean biotechnology industry .. 
27. BIOPROCESS TECHNOLOGY is u cruchsl tHchnology. JJioprocesses are 
systems in which complete livin~ cells or tht,ir components (e.g. 
enzymes, chloroplasts, etc.) are used to effect desired physical or 
chemical changes.(41) The advent of new biotechnology has sparked 
renewed interest in the industrial use of bioprocesses, because in 
most cases they are the only practical way in which a desired product 
can be formed.(42) In particular, the development of techniques for 
the immobilization of biocatalysts has greatly expanded the pos-
sibilities for continuous bioprocesses and more effective bioprocess-
ihg. ( 43) 
28. The Japanese companies are known for their experience in large-
scale bioprocessing, especially in the field of plant biotechnology 
and enzyme technology.(44) This will provide them competitive 
-:;trengths in many future biotechnology markets, although it must be 
kept in mind that the Japanese companies are particularly strong in 
the older techniquei::,. 
29. The United States, with an assortment of companies supplying 
biochei,ii cal reagents, instnunen ta tion • and so£ tware, has the strongest 
biotechnology support sector in the world .. (45) Ac.cording to the 
authors of Commercial Biotechnology this is due to two factors:(46) 
a. The United States is a recognized leader in basic biomedical 
research, and over the years, public funds, notably from the 
National Institutes of Health, have created a large well-defined 
market for speciality products used in biological research. 
b. Because so many large and small U.S. companies are currently 
applying biotechnology. the speciality research product needs are 
greater in the U.8. than in any other country, and opportunities 
exist for inany small manufacturers. 
·30. In a recent report on "Emerging Membrane Separation Technologies" 
by International Resource Development, the importance of the biopro-
cessing separation and purification (filtering) technologies is stres-
sed. The market for separation products will be worth$ l{X) m. by the 
end of the decadeo(47) As large-scale production draws closer, the 
ability to isolate and purify large quantities of desired products 
will be a determinant in how fast companies can reach international 
products markets. Those countries that possess the most advanced 
technology to separate and purify commercially important compounds 
might gain some commercial advantages in the early stages of produc-
tion. In the US, JB-pan and Europe there is an intense competition in 
R&D to develop more advanced eeparation and purification methods as 
well as for monitoring und controlling a bioprocesa itself. In par-
ticularly in autoauate<1 synthesis and the use of sophisticated in-
strumentation to monitor and control, the US companies hold a strong 
~ompetitive position. The only European firm that has a strong posi-
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tion in this field is Pharmacia, a Swedish firm.(48) 
.31. This illustrates the weak position of the European Community and 
stresses the need for a joint European effort in the entire field of 
downstreaming process equipment since it is the crucial chain of 
identifying promising new products and services. European support will 
be needed since the research (arid investments) needed are beyond the 
resources of mosl of the (smoU~r and medium-sized) firms. Further-
more, the European market for downstream processes is a growth market 
and can lead to many new, high qual:lfied jobs and to many new small 
specialized firms. In the Commission's proposal . more attention 
should be paid to the potential of this sector. 
32. The development of BIO-INFORMATICS~ a term which is used to refer 
to the various topics at the interface between information technology 
and biotechnology, is essential. The volume of information becoming 
available is such that it demands automated, high-speed reading in-
~truments and methodsa(49) In the Proposal of the Commission it is 
stated that for the support of bio-informatics more research is needed 
in the field of: (50) 
- data capture technologies 
- data banks 
' - computer models 
- advanced computer software systems= 
These efforts are closely linked to other information gathering war-
.king groups in the Community (e.g. ~PRIT, The Task Force on Biotech-
nology Information and the European Molecular Biology Laboratory). 
The creation of European databanks and European molecular software 
implies concentration and centralisatioqG The information should be 
made available to users throughout the Community (and perhaps also to 
other European countries) to stimulate a faster diffusion of knowledge 
and research results and to build up a supporting infrastructure. Such 
an information system can only be successful if the big private compa-
nies collaborate~ Therefore negotiations with these companies should 
be undertakenG Another problem that should be discussed further, in 
particularly with reference to paragraph II.6 0 is the guaranteed 
global access to databanks and biotic collections. 
33. The development of SOFTWARE designed for molecular biology and 
bioprocessing is almost entirely concentrated in the United 
States.(51) Software is very important, because it controls all the 
automated processes. The US company Intelligenetics is specializing in 
the application of data processing anq artificial intelligence tech-
niques to biological problems and this company has created specific 
software packages to assist researchers with molecular genetics 
analysiso(52) A growing dependence on American software suppliers can 
lead to an j·nsufficient exploration of possible, specific European ap-
plications of biotechnology. 
VI~ HOW SERIOUS IS THE BIOTECHNOLOGY BRAIN DRAIN FOR THE EC? 
34. In recent years concern has been expressed at the movement of 
European biotechnologists (especially from the United Kingdom and 
West-Germany) to other countries. Although we can speak of an internal 
- brain drain inside the European Community (especially from the United 
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kingdom to the continent) 9 the problem of the brain drain to the 
United States and Switzerland seems to be more serious. 
35. In 1983 the Institute of Manpower Studies (IMS) made a study on 
this subject for the situation in the United Kingdomo A rough estimate 
suggests that there may be some 250 UK biotechnologists who have left 
since the mid-1970's and are working ov~rseas, if young post graduates on 
short term contracts are included. This is about 15 per cent of the 
total number currently employed·in t.he UK .. The annual outflow could 
have been of the order of 30 per annwn in the last two years .. (53) 
While this loss ha!j not htad u signif.lcsnt impact on many individual 
organisationao it waH seen as an important reduction of the UK's pool 
of biotechnology expertise. The main reason for leaving the UK was the 
non-availability of 'suitable' opportunities and jobs in the UK. At 
senior levels it was the attraction of new opportunities that led them 
to move overseas.(54) The majority did not expect to return to the UK. 
The Research Councils. the UKis public research institutes~ have 
adopted an active policy of encouraging scientists from the United 
KingJ0m who have spent time in industry abroad to return homee (55) 
36m The Federal Republic of Germany has sufficient personnel to com--
_pete with the United States and other countries in biotechnology. The 
training of people in rDNA and hybridoma technology is now a high 
~ ·ority in West Germanyo Like the United Kingdom, West Germany is 
cc... 1~:erned about a brain drain of biotechnology R&D personnel, because 
of Lhe increasing need of high qualified people in this field. Shor-
tages of suitable qualified workers in West Germany are partially due 
to braj.n drain to the United States.. The problemp however, appears 
here to be less serious than in the UK .. (56) 
37a _france has a serious shortage of qualified personnel that could 
well underm.i.ne the country's basic and applied science base and pre-
vent France and its industries from competing successfully in the 
world biotechnology marketplace, despite the fact that France has some 
isolated centres of expertise~(57) 
380 To prevent a further brain drain the European Community has to 
build up a biotechnology industry .. An internal European "brain flown 
should take place~ e.ga from the universities to the industry and vice 
versa. In Europe, there is a serious shortage of trained biotechnolo-
gist with a multidisciplinary b~ckground~ It is positive that the 
European Commission has stressed the training aspect very strongly, 
because without enough qualified personnel biotechnology has no future 
in Europe. In particularly for the smaller countries» where the lack 
of trained manpower is sometimes more evident, the training facilities 
will be welcome& However, the training programmes should have an 
additional character and should be substantially different from the 
training programmes in the Member Statese The industry should also 
contribute (in a financial way and also with staff) to the esta-
blishment of these programmes 9 because it is largely in their 
interests~ The training should also contribute to further ba@ic re-
search~ To concentrate on the short term applications of biotechnology 
and to neglect further bacic research could hamper applications in the 
medium- and long run~ Also more attention should be paid to on-the-job 
training and various scientific exchange systems.(58) 
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VII. THE NEED 1"1>R A PROFOUND RESTIWCTUR t~G OF AGRICULTURE 
39. One of the goals of the Research Action ProgrHmme Biotechnology 
(•the Commission proposal> is the promotion of agricultural 
competitiveness by research and training, concertation and by promo-
ting closer relations between industry and agriculture. Other goals 
closely related are "improving the management of raw materials" and 
"reinforcing development eid" 0 in which basic research for agriculture 
is stimulated. ( 59) Several re,rnon!J can bt! gt vcn for the strong empha-
sis on the (medium- and longtcrm) pro1apects of biotechnology for 
agriculture: 
a. although biotechnology applications or~ now more concentrat~d in 
pharmaceuticals, the market for !.E!..£::!.22..~ products is estimated 
to be much bigg~ than the market for pharmaceuticals .. (In the US 
the market for agricultural products is ttclose to ten times the 
size of the market for all pharmaceutical health care pro-
ducts"). ( 60) 
b. biotechnology can also allow iffiproved .land us~, and. in 
particular the replacement of surplus production by products of 
which there is now a shortage such as woodo(61) 
c. the implementation of new biotechnology methods opens up pros-
pects for the upgrading of agricultural products and can lead to 
some degree to a reduction of national and Community support for 
agriculture;(62) 
40. The second reason will demand a ~~prais2.1 of the use of land. 
Some traditonal agricultural products risk to become superfluous, 
which will make it both highly PXJ.l(•uai vc anct u] timately wasteful to 
continue subsidising or encournglng thPir production.(63) This will 
cause serious conflicts between var10trn tnterest groups Jn the Commu-
nity. A carefully balAnccd rcstruct~r!ng poli~Ltowards the regions 
(and agricultural products) concerned is necessary to prevent d\sinte-
grating and to avoid further unequal regionHl developrnent inside the 
Conununity. Regions that will be negatively aff~cted should be informed 
in time and must be stimulated to switch to other higher value-added 
products. This demands a well organized informations policy, not only 
towards industry, but especially towards farmer organizations and 
other direct involved i~terest groups. 
41. In its Communication on the Cor.unon Agricultural Policy (COM(83)500 
final, 2.10) the Commission haA underlined the necessity "to provide 
Community raw materials for biotechnology on the same conditions of 
competition as for external competitors."(64) In its Proposal the 
Commission suggests new :.e imes for suQar and starch for industrial 
use which will attain these objectives.(65 The system of lower 
prices for agricultural products that are used as industrial inputs is 
already applied in Belgium and Ireland. The reason behind these new 
regimes is that European industry is reluctant to buy Coimnunity agri-
cultural surpluses, because prices are much higher than the world 
market prices for sugar, starch, milk). Some companies in the 
Community accordingly set up production units in countries such as 
Austria or Spain, where the prices of primary commodities are based 
on world market pricesp and not primarily oriented on the producers (as 
are subsidized prices). The processed products are then re-imported 
into the Community. For the Community these practices worsen the 
agricultural situation substantially: support for the farmers remains 
and the surpluses grow. lower prices for agricultural products 
can stimulate new industrial processes and can help to decrease 
surpluses. It is possible that lower prices will stimulate 
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· farmern to switch production o It i.::; likely, however II that this will 
not be a smooth process. The lower prices can also contribute to 
substantial lower income on farm level .. In fact the farmers are in a 
dilemmao This is especially the case for sugin-·beet-farmers: they have 
to sell their sug&rbeets against far lower prices (otherwise they have 
an enormous production surplus)~ but the biotechnology makes it possi-
ble to produce other swectenen~ w like isogl ucose O fructose and aspar-
tham o which arc nu:rny more limeH HwecttJr thun sug&:r l',md $Ometin1ca niuch 
cheaper • 
42Q The further development of industrial biotechnology in e1 commer-
cially sound manner will require changes in the 0 ~rotectioniatu atti-
tude of particular sec tor inten;.~sts Q In. particularly II when ~agro-
products are used as feedstock$, tlirlffs for commodity chemicals and 
the associated feedstocks will have to :reflect world market prices and 
cannot be based on sourcing~(ti6) This demands a profound change of 
!!Sricultural policx~ In this context only some of the arising problems 
.can be mentionedo They should be studied far more extensively than 
hi.therto done to prevent a second gsteel-debacle 0 in the nearby fu-
ture. Subjects for further study (eag@ in the frame work of the 
v9SYRENA" - FAST-research programme)(67) are aoo .. : 
The time-horizon of the application of biotechnology on a la~ge 
scale to agriculture, and consequences for regional development 
and employment (regional inequalities, uneven adaption of new 
technologiesi income inequalities at the farm level 0 increased 
scale, labor displacement 0 rising land prices 0 genetic erosion 0 
etc.,) 
An analysis of agro-products that will have a multi-purpose use 
(foo<l~ chemical feedstock, en.19rgy) and the posaiblities for swit-
:...htng production in the different regions o.f the Community .. 
The possibilities of starch ea a feedstock for chemical and fuel 
production and the consequianct!a for food productiono Will starch 
be produced in large enough quantities to be used both as a 
source of food and a source of energy? 
An analysis of the effects of biotechnology on the organizational 
and social relations of 0 traditional g farming tm,ya:rds ubio-ma.na-
gement O ~ 
Political constraints will arise as a result of the unequal 
development and diffusion of biotechnology in the different Mem-
ber States an~ regionso To what extents will.politicat- conflicts hamper the 
restructuring of agriculture policy in the Community? 
43a In this limited context one subject for further research must 
receive more attentiono This is the st1fategical position of the seed-
industryo Many of the corporations inveating heavily in biotechnology 
are those that have been active in aquiTing se~d CO!llllipsnies ©Jver the 
last decadeo In particular~ petrochemic~l and pharamaceutical transna-
tional corporations have important agroch~mical tnterests" These com-
pamies a.re v.r1ell situatec: to dominate. the gene :revolution in ag:ricul-
ture o Apart from a few vegetatively propagated crops@ there is J)J2. 
othe:r way to bring bioengineered plant viarrietieg;i to m®:rket except via 
the seed., Few of the remaining smsllD independent B!e®d firms have the 
same possibilities and <·apabi lities as the trsnen.ationsl~o These small 
companies will disappe8r orp as is more likely~ be absorbed by larger 
firmso A serious danger lies in the fact that seed compani~Sp and by 
extension their transnational parentsp ~re c~pabl~ @i e~tti~g their 
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own breeding agendas according to their own commercial criteriona{68) 
It is very well possible that agricultural research, which is a public 
sector activity in most countries, will become dependent more and more 
on these seed companies~ This should be prevented 9 because it implies 
the loss of an important institutional mechanism for the exertion of 
social control over the development and deployment o.t 
biotechnology.(6Y) 
VIII. BIOTECHNOLOGY AND PROSPECTS FOR REGIONAL DEVELOPMENT A.ND 
EMPLOYMENT 
44. The development of biotechnology will certainly change many exis-
ting social, economic and political structurese It is beyond the scope 
of the report to assess the possible impact of biotechnologye More 
research is needed on the changing international division of labour 
·and on the practical consequences for the people directly involvede 
45. The combination of biotechnoloay and microelectronics makes it 
possible that regions will develop more autonomously and less depen-
dently. A quick diffusion of microelectronics (computers 0 telecommuni-
cation networks, flexible automated systems) makes decentralisation on 
a large scale possible~ This also implies that backward regions will 
be able to compete with more developed regionsa The use of biotechno-
logy makes it possible to use renewable resources and to use them ·for 
several purposes.They can be u~ed for food productionv for energyD for 
the chemical industryp for pharmaceuticals etc .. With less material an 
ever increasing result can be reached (''dematerializing of products") o 
(70) Improved logistics can prevent surpluses and deficiencdes ... This 
means that regions can become less dependent on imports in general and 
that a more balanced development is achievedg 
46. The above described positive scenario implies equal access for 
regions to the new technologies and the wish of industry and services 
to decentralize. In reality, howeveri the political strength of the 
· different regions (and countries) is · ~ equal 0 end, therefore it is 
foreseeable that some regions will profit more than other regions. It 
is likely that the developed agricultural regions in the Northern part 
·of the Community will switch faster to new~ more value-added agricul-
tural products. These regions can build up strong ties with the ari-
·sing biotechnology-industries» which also will mainly develop in the 
Northern part. The Southern part of the Community has less access to 
the new technologies and has less possibilities of application. The 
necessary infrastructure (informatics) is also less developed and this 
·will be an additional diaadvantageo In the most positive case, these 
.regions will produce less value-added agricultural products for a less 
developed biotechnology-industrye It is a political challenge to deve-
_lop a balanced regional policy in the Community that explicitly pays 
-~ttention to the impact of unequal (bio)technological diffusion. 
47. Biotechnology will not lead to an important increase in 
·EMPLOYMENT. The major technological trajectories of the future (bio-
technology and microelectronics) are all labour saving. As a con-
sequence, employment in almost all sectors of the economy will 
decrease, and Europe will at best know a situation of jobless growth. 
The impact of the jobless growth situation will be different for the 
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various regions.(71) A strong (further) decrease of job opportunities 
in agriculture is likely to occur.(7'1.) The new trujectories have also 
an influence on the type of labour required and on the 
quality of labour. In general one may say that the lower skilled 
workers are replaced by new machlnery and equipmentf and that it will 
notably be the highly 4.ualified stuff for all types of computer re-
lated activities that will dominate the demand of the labour market in 
the future. 1his implies that it will also be the availability of 
highly qualified personnel that in the future will determine the 
location of economic activity (whereas it was the number of semi-
qualified workers that dominated location patterns in the past).(73) 
480 Biotechnology will generate only a modest increase in employment 
opportunities for highly specialised scientists (R&D, education & 
training, consultancy) and for biomolecular software writers.(74) 
However, highly computerized sophisticated instrumentation (biosen-
sors» computer-coupled bioprocess~s; software packages) will facili-
tate fast automation, which reduces the labor intensity of laboratory 
ta5~<.s. (75) The same can be said about the employment prospects for 
bio-informatics. tiere also, much of the work will be highly auto-
matedo(76) 
g:. TP~~ POSSIBLE IMPACT OF BIOTECHNOLOGY ON THE THIRD WQBLD 
~~9, There has been widespread recognitton of the 2otential value of 
bioicchnology to the developing countries (~LDC's)~ Many of the possi-
ble application6 of biotechnology are laid down in a recent FAST-
study.(77) In the nPlan by Objective,, Biotechnologyu~ it is stated 
that 81 Europe 1 s biotechnology can offer know-how, hardware and genetic 
material, which can improve "bio-syatem management'° in the LDC's. 
Europe could also contribute to biomass energy production and to 
biomedical science~(78) It could be asked, however§ how far these ideas 
are expressions of wishful thinkingo One must recognize that the 
.improvements in agriculture and industry as a :result of biotechnology 
will be accompanied by strains and dislocationssi both economical and 
social. For example, the development of biotechnology has heightened 
conflicts between industrial and less developed countries over access 
to and control over germplasm resourceso(79) Biotechnology processes 
threaten to undermine export markets for raw materials (e .. g. sugar: ·). 
It is also possible that the bio-revolution will extend the process of 
displacement to heretofore marginal areas where subsistence and petty 
commodity production has persisted.(80) And~ although bioengineered 
crop varieties adapted to low levels of fertility or tolerant of 
saline ground could raise food production in vast areas of the Third 
World, it is also clear that no commercial seed firm is interested in 
developing plant varieties for those who cannot pay for them.(81) The 
transnational agribusine.::.-i.:::: is~ however, interested in the Third World, 
but for other reasons: hf~re they find a §OUrce gf my.eh needed genetic 
diversitya(82) A aerious danger might arise ~~!~-~~§_}!S9!!t!\._!~.!'=-
ting __ ground_for_humanly_engineered_bacteria that are banned elswhere. 
Another danger Hes in the genetic erosion (the loss of valuable 
genetic plant information) as~ result of monopolizing activities of 
large seed companieso(83) 
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50. Analyzing the distributional character of the new technologies 
becomes crucial if a serious effort is to he mounted to shift the 
distributional patterns of biotechnology in an~quity-enh§ncing (or at 
least, less inequitable) dtrectiona(84) Therefore we have to pose the 
basic questions involved in technological assessment: Who gets yh@t, 
when, where, whv, how, ang.,..boy mu~tt~ This is a political task. 
51. Biotechnology in turn offers the possibility of bringing about 
dramatic changes in human health through new drugs and in human nou-
rishment through vastly incTeased agricultural production. But access 
to the knowledge about biological systeme should be guaranteed. It is 
a very positive development tht"1t the JlNJJ)Q. has set up two Internatio-
nal Centers for Genet i.c. Eng1naex$1.ng & Biotectmology (TCGEB) (in Trieste 
and in India) to aid developing countriese(85) C.,9operption between 
these institutes and the Community~s Biotechnology Programme should be 
stimulated, e.g. in the framework of the sub-programme medicine, health 
and nutrition in the tropics. Alsop scientists from LDC's should get more 
access to training centers in Europe in order to establish (informal> networks 
or other forms of collaboration (information collection, data banks, cell 
banks, grants, seminarsp etc.)u The Community should support the 
development of networking financially0 
X. PATENT PROTECTION IN BIOTECHNOLOGY 
52. In 1982 the OECD distributed s questionnaire on "Patent Protec-
tion and Biotechnology"& In July 1984 a synthesis report was presen-
ted. This report was based on the replies given by 19 OECD-Member 
countries.(85) The major reason to focus on patent protection in 
biotechnology is that the sterttng material, the microorganism, is 
living and self-:replicatingo · which sep~ra tee microbiological from 
other inventions. The central question in the discussion is the form 
in which patent claims could be granted for microorganisms, if at all, 
and the availability of so-cdled .2.,er s@ claims, as well as those 
commonly described as "produc.t by proceHvt claiu.(86) 
53. In no other field of technology do _pationsl 1@.p yary on so many 
points and diverge so widely as they do in biotechnology. It appears 
that United States law and Japanese law are on the whole more open and 
flexible towards new developments in biotechnology than are the laws 
of many other OECD countriese(87) International investors in bio-
·technology prefer. those countries which afford strong and effective 
patent protection, i.e. the United States and Japan.(88) The same can 
be said for inventors.(89) The new Drug Bill adopted by the U.S. House 
of Representatives on September 6, 1984 9 provides up to five more 
· years of patent protection for new brand-name drugs.(90) This can be 
an extra incentive for European firms to patent in the US and to 
transfer research and production as well. 
543 Considering the international dimen~ioQ of biotechnology activi-
ties and the ease and speed with which the main starting material of 
the new industry can be taken sway and cultivated, a h@QIPQisatigp of 
patent protection is needed~ An agreement on harmonisation should be 
established at OECD level, because an agreement at Community level 
alone implies differences with our main competitors. However, this can 
take a long time. Therefore, the efforts of the Commission 
to draw up a document on the situation in the Community on 
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intellectual property rights in the field of biotechnology (91) 
have to be enforced. 
XI. LEGAL AND ETHICAL PROBLEMS RELATING TO GENETIC ENGINEERING 
55. It is expected that in the nearby future tensions will arise 
between "pure scientHic and economic" interests (freedom to do re-
search) and more ethically inspired interests., This will especially 
occur in research relating to human genetics such as the manipulating 
of embryos. In the Committee of experts on Ethical and Legal Problems 
relating to Human Gentics (CAHGE) it was accepted that this should be 
restricted to therapeutical use and that it would be useful to draw up 
guidelines.(92) We have to ask what is meant by .. therapeutic". It 
seems that this still leaves enough room for less desirable manipulatin~9 
Also the problem of embryos should be studied further. In general, we 
have to ask, whetqer everything that is technically possible is 
also desirablea A discussion on this question should not be restricted 
to a small group of experts and representatives of governments and 
industry (who often discuss restricted papers)e The implications 
of biotechnology and genetic manipulation are such that a much broa-
der public should discuss these problems.(93) 
56. In the various Member States of the Community different norms and 
regulations are applied to work involving recombinant DNA. From an 
updated picture on the situation of legal regulatiom in Council of 
Europe Member States it appeared that the United Kingdom is the only 
Community Member State which possesses a legislation covering DNA 
research.· In the other Member States other provisions are made, but 
not in all countries. Sometimes safety of recombinant DNA research is 
only provided by guidelines that are followed on a 'voluntary' basis 
(Ireland) •. · To safeguard workers a common legislation (guidelines) 
should be established. It is said sometimes that working with DNA 
involves less hazards than was expec.ted. Therefore, the earlier men-
tioned CAHGE-committee added a paragraph just before the Principles of 
thb Recommendation (82/472/EEC. concerning registration of work invol-
ving recombinant DNA), stating that these Principles apply only to 
work involving recombinant DNA which may present a bio-harzard of a 
category which will be determined by each State (i.ea the work having 
a bio-risk less than this minimum or no risk will fall outside the 
·application of the Recommendation)J94Y This is a very regrettable 
development. Who determines the minimum risk-level? ls enough known 
about the possible hazards? Does such a multi-interpretable text 
protect workers (and others) sufficiently? As long as we do not know 
. all the possible consequences of working with recombinant DNA no 
deregulating steps may be takene This is a political responsiblity. 
57. Laboratory risks and risks in 'scaling-up' or testing in 'open 
field' are not comparable.. Technology assessment of the latter is extre-
mely difficult, because beside biological risks, social, economical, 
environmental, legal and ethical impacts should be considered. Before 
this assessment is made (it should be a part of the biotechnology 
proposal) NO manipulated microorganisms should be allowed to leave· 
laboratories for testing or scaling upa 
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XII. THE PROPOSAL OF THE EUROPEAN COMMISSION FOR A MULTIANNUAL 
RESEARCH ACTION PROGRAMME: Tfm""-~1AIN CRITICAL FQI)~i'So 
58. In its preparatory studies the Commission has clearly shown the 
need for a European biotechnology action programme. In the last iew 
years many important aspects have been dealt with. It is hard, how-
ever, to find a reference to ell these aspects in the Commission 
Proposal COM(84)230. The Proposal is more or less a summarized "task 
list". The central task is the effective management and use of infor-
mation. Therefore the Commission suggests,the establishment of a con-
certation unit on biotechnology (CUBE) tha~ has a monitoring task and 
has contacts with other policy areas, and national and international 
orseni&$tion!. A too strong concentrationf on organise~ interests (es-
pecially in industry and agriculture) can lead to an involvement of 
Community that goes far beyond 'pre-competitive' research. An impor-
. tant task of CUBE should be to inform in particularly those sectors· 
(e.g. small- and middle sized firms, trade unions, regional and local 
politicians) in the Community that are less aware of t'he transforma-
tion biotechnology is likely to provoke. 
59, In the Resolution of the Report of G. SCHMID on biomolecular 
en,ineering (Doc 1-521/SO)it is stated that the Commission should prove 
an economical and social need tor biotechnology and should make clear 
what the implications of intensive use of biotechnology are for socie-
ty. The Commission succeeded in the first, but . .,,. i al though some attempts 
where made in the FAST-programme- did not succeed in the latter. 
60. In all its reports and analyses the Commission stresses the multi-
disciplinary character of biotechnology and the diversity of applica-
tions. Less attention is ~~id, however, to the assessment of bio-
technology and genetic engeneering. The pervasiveness of biotechnology 
is such that almost every economic activity will be affected. The 
combination of microelectronics and biotechnology will speed up this 
process. This implies that assessment problems will occur much faster 
than is foreseen. Therefore the Commission should develop an extensive 
Biotechnology Assessment Programme wi di respect to all problems rela-
ting to political, economic, regional, legal, environmental, and ethi-
C&i impacts. · 
6·J.. The necessity for restructuring of agriculture policy in the Community 
as a result of biotechnological development is not elaborated enough in the 
..... 
proposal. This, however, will be of crucial importance for the development --,,;1 
of biotechnology in the Community. As suggested earlier more research 
~as to be done. This can provide a basis for political discussion. 
62. The Biotechnology Action PrograJnme cannot be more tha.n a ,catalyst 
to stimulate the development of biotechnology and to assess the 
possible risks. The Commission should seek support by national autho-
rities, institutions· and industry that could act as co-financers. 
Duplication of research (that already take place in the Community or 
in the US) should be avoided. 
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63. It is a very positive development that a cooperation will be 
established between the Biotechnology Action Programme and the ESPRIT 
project (information technology), and CIDST (•Conunittee on Information 
and Documentation for Science and Technology). It is unclear, however, 
how the collaboration will take place and pow overlap will be avoided. 
64. The need for multidisciplinary trained scientists has been stressed. 
The experiences with the training programme in biomolecular engineering 
confirm this. However, it is questionab~e'whether the Commission can 
provide enough training facilities to train' substantially more scientists 
than will be trained in the national Member States anyhow, this will 
largely depend on the willigness of the Member States to cooperate financially. 
European training facilities, how limited they are, should also be 
accessable for scientists of the developing countries. 
65. Only those middle and long term projects should be financed by 
the Community that would not have be~n set up by the industry and 
agriculture itself without the financi31 support of the Biotechnology 
Action Program.me. 
66. In the Programme the Commission should build in a condition that 
contractants will have to repay (partly) research costso if they 
succesfully commercialize the results of research that is carried out 
·within the framework of the Programme o • 
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OPINION OF THE COMMITTEE OF BUDGETS 
Letter from the chairman to Mr PONIATOWSKI, chairman of the Committee on 
Energy, Research and Technology 
Luxembourg, 1 October 1984 
Subject: Proposal from the Commission for a decision adopting a multiannual 
research action programme of the European Economic Community in the 
field of biotechnology (1985-1989) (COM(84) 230 final -
Doc. 1-335/84) 
Dear Mr Chairman, 
The Committee on Budgets considered the abovementioned Commission proposal at 
its meeting of 20 September 1984. 
The committee welcomed the fact that the Commission proposes to take an 
initiative in this important fielda It noted that the planned volume of 
expenditure chargeable to the budget of the Communities would be 88.5 m ECU 
over a five-year period and 26 additional posts would be required in that same 
period~ It was also noted that this research programme fitted in closely with 
the guidelines laid down in the framework programme of Community scientific 
and technical activities for 1984-1987, which was endorsed by Parliament in 
June 1983. In particular, the biotechnological component of the programme for 
the period 1985-1987, and the biomolecular engineering component for the 
period 1984-1986, would be covered in the total appropriations of 80 m ECU set 
aside for biotechnology under the framework programme. 
The committee applauded the emphasis placed on rationalizing the organization 
of research within the Community, especially as regards the avoidance of 
duplication between national research efforts. It agreed with the 
Commission's view that cooperation at Community level would make budget 
spending more effective. 
The Committee approved the principle whereby third countries could participate 
in the programme provided that they bore a portion of the related costs. 
The Committee on Budgets wishes to draw particular attention to the following 
points: 
1. The appropriations entered in the 1985 budget, needed to finance studies, 
pilot projects and similar activities, can be implemented immediately 
after 1 January 1985p even if the Council has omitted to lay down the 
corresponding legal basis, given that the budget provides a sufficient 
legal basis for the implementation of appropriations. 
2. The precise volume of appropriations for this programme can be determined 
only by the budgetary authority when it lays down the budget for 1985, and 
will largely depend on what resources are available. 
WG(2)1335E 
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3. The role of the management and consultative committee must be confined 
purely to consultation: in particular? its responsibilities must not 
encroach on the budgetary powers of Parliament, nor must they restrict the 
Commission•s responsibilities with respect to management, as provided for 
by the Treaty. 
The committee also stressed how important it was to coordinate all the 
Community policies having a bearing on this sector, to prevent conflict from 
arising between them. It questioned in particular whether the organization of 
the market in sugar would be compatible with the action proposed. 
Yours sincerely 
{sgd) Jean-Pierre COT 
The following were present: Mr COT, chairman; Mr CURRY, vice-chairman; 
Mr ARNDT, Mr BARDONG, Sir Fred CATHERWOOD, Mr CHAMBEIRON, Mr CHRISTODOULOU, 
Mr CORNELISSEN, Mr DANKERT, Mr DEPREZ, Mr ELLES, Mrs FUILLET, Mr HABSBURG 
(deputizing for Mr PFENNIG), Mr LANGES, Mr NORMANTON, Mr SCHREIBER (deputizing 
for Mr ABENS), Mr VARFIS and Mr de VRIES (deputizing for Mr ROSSI)a 
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OPINION OF THE COMMITTEE ON 
ECONOMIC AND MONETARY AFFAIRS AND INDUSTRIAL POLICY 
Letter from the committee chairman to Mr PONIATOWSKI, chairman of the 
Committee on Energy, Research and Technology 
Luxembourg, 18.10.1984 
Subject: Multiannual research action programme of the European Economic 
Community in the field of biotechnology (1985-1989) 
Dear Mr Poniatowski, 
In its framework programme for Community scientific and technical activities 
1984-1987(1) the Commission, fully supported by the Parliament, assigned a 
high degree of strategic importance to biotechnology as a means to improve 
European industrial competitivenessa 
Biotechnology has major implications in such fields as agriculture, food, the 
environment and health. 
Our committee, therefore, welcomes and approves the Commission's proposal 
adopting a multiannual research action programme of the EEC in the field of 
biotechnology (1985-1989)(2). 
Our committee, however, underlines the need for the following: 
1Q proposals by the Commission covering the other four actions mentioned in 
the September 1983 communications (3); 
2o adequate financial resources in order to permit a thorough development of 
the programme; 
(1) Doc. 1-395/83 
(2) Doco 1-335/84 
(3) COM(83) 672 fin./2 
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3. adequate staff and an increased use of informatics in the administration 
of the programme; 
4. the inclusion of medical subjects in the research programme; 
5. a fair and adequate diffusion of the results of research, duly taking into 
account regional disparities and problems faced by SME • 
This letter should be considered as the opinion of the Committee on Economic 
and Monetary Affairs and Industrial Policy (1)o 
Yours sincerely 
Barry SEAL 
(1) Members present: 
Mr SEAL, chairman; Mr BEAZLEY, vice-chairman; Mr BONACCINI, Mrs 
BRAUN-MOSER (deputizing for Mr von BISMARCK), Mr CHRISTODOULOU (deputizing 
for Mr ERCINI), Mr CRYER (deputizing for Ms QUIN), Mr GAUTIER, Mrs van 
HEMELDONCK, Mr HERMAN, Mrs de MARCH, Mr METTEN, Mr MUHLEN (deputizing for 
Mr STARITA), Mr NORDMANN (deputizing for Mr WOLFF), Mrs T. NIELSEN, Mr 
RAFTERY, Mr ROMUALDI, Mr ROGALLA, Mrs van ROOY (deputizing for Mr ABELIN), 
Mr WAGNER, Mr WE.EKIND and Mr van WOGAU 
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OPINION OF THE COMMITTEE ON AGRICULTURE, FISHERIES AND FOOD 
Letter from Mr TOLMAN, chairman of the Committee on Agriculturep Fisheri~s and 
Food to Mr PONIATOWSKI, chairman of the Committee on Energy, Research and 
Technology 
Brussels, 26 September 1984 
Dear Mr Chairman, 
At its meeting of 26 September 1984, the Committee on Agriculture, Fisheries 
and Food C1) examined the proposal from the Commission for a Council decision 
adopting a multiannual research action programme of the European Economic 
Community in the field of biotechnology (1985-1989). 
The committee sees the present proposal as a Logical development in the 
Community's programme of research in the field of biotechnologym 
In the opinion by Mr GAUTIER of 30 May 1983 (PE 84.311/finm) on a European 
scientific and technical strategy, my committee welcomed the possibilities 
offered by biotechnological research for improving the competitiveness of 
agriculture and fisheries. It was however, pointed out that conflicts may 
arise between agricultural policy on the one hand, and research in 
biotechnology on the other, since most agricultural raw materials for 
biotechnology are subject to market organizations whereas the biotechnological 
end products are not and may therefore be imported either duty-free or at 
fixed rates. 
The Committee on Agriculture, Fisheries and Food fully supports the present 
proposal and urges the committee responsible to monitor implementation of the 
decision closely. 
Yours sincerely 
T~ TOLMAN 
(1) The following took part in the vote: Mr Tolman, chairman; Mr Eyraud, 
Mr Graefe Zu Baringdorf, Mr Mouchel, vice-chairmen; Mr Battersby, 
Mr Bocklet, Mr Borgo, Mr Christensen, Mr Clinton, Mr Crawleyp Mr Dalsass, 
Mr Ducarme (deputizing for Mr Maher)p Mr Ebel (deputizing Mr Debatisse), 
Mr Fanton, Mr Fruh, Mr Gatti, Mr Guarracip Mr Guermeur (deputizing for 
Mr MacSharry)p Mrs Jepsen, Mr Klinkenberg (deputizing for Mr Sutra), 
Mr Linkohr (deputizing for Mr Woltjer), Mr Marckp Mrs Se Martin~ 
Mr Mertens~ Mr Mussop Mr B. Nielsen# Mr Fs Pisoni, Mr Provan, Mr Romeos, 
Mr Rothep Mr Stavroup Mr Stirbois, Mr Taylor (deputizing for 
Sir Henry Plumb) and Mr Wettig. 
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OPINION OF THE COMMITTEE ON THE ENVIRONMENT, PUBLIC HEALTH 
AND CONSUMER PROTECTION 
Draftsman: Mr G. SCHMID 
At its meeting of 20 September 1984# the Committee on the Environment, Public 
Health and Consumer Protection appointed Mr SCHMID draftsman of the opiniona 
The committee considered the draft opinion at its meetings of 30 October and 
21 November 1984. On 21 November 1984, it adopted unanimously the draft 
opinion and its conclusions. 
The following took part in the vote: Mrs Weber, chairman; Mrs Schleicher and 
Mr Collins, vice-chairmen; Mr Schmid, draftsman; Mr Alber, Mr Avgerinos 
(deputizing for Ms Tongue), Mrs Banotti, Mr Cottrell, Mr Dalsass (deputizing 
for Mr Mertens), Mr Falconer (deputizing for Mr Vittinghoff), Mrs C. Jackson, 
Mr Lambrias (deputizing for Mr Parodi), Mrs Lentz-Cornette, Mr Muntingh, 
Mr Pearce, Mrs Peus (deputizing for Mr Michelini), Mr Roelants du Vivier, 
Mrs Rothe (deputizing for Mr Bombard), Mr Sherlock, Mrs Squarcialupi, 
Mrs Van Hemeldonck (deputizing for Mr Hughes), Mrs van den Heuvel (deputizing 
for Mr Tognoli) and Mr van der Lek. 
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A~ INTRODUCTION 
The European Parliament has aleady given its approval in principle to a 
Community biotechnology programme in its 1980 opinion on the biomolecular 
research programme (Doc. 1-521/80). The proposed expansion of this programme 
must, however, be examined to see whether it takes due account of the 
following aspects: 
the risks of genetic engtneoring for man and the environment, 
applications in medicine, 
contribution to environmental protection, 
Lower production costs with resultant drop in consumer prices. 
The Commission proposal takes only limited notice of these points. The 
Commission describes the main aim of the programme as the promotion of 
agricultural and industrial competitiveness and asks industrial enterprises to 
submit their research projects. Industry, however, makes its decisions on the 
basis of expected profit and not of social needs .. Promoting the application 
of biotechnology in the above areas does not follow from the Logic of the 
market but requires a political decision. The Commission proposal therefore 
needs to be supplemented .. 
B. SUGGESTED AMENDMENTS TO THE COMMISSION PROPOSALS 
To the Preamble: 
Amendment No .. 1: 
Complete first indent as follows: and for Lowering production costs' 
Amendment No .. 2 
After second indent insert new indent to read as follows: 
0 
= Application of biotechnology to enviromental protection' 
Amendment No~ 3 
Ater third indent insert new indent to read as follows: 
0 
- Replacement· of animal experiments with tests on cell cultures' 
Amendment No .. 4 
In the fourth indent delete the word 'costly' 
Amendment No., 5 
Amend fifth indent to read as follows: u ••• associated with the application 
of biotechnology.m 
Amendment No .. 6 
Complete the antepenultimate recital as follows~ 
0 and these developments must also be monitored so that problems of a socialp 
ethical or ecological nature which may arise from the use of such technology 
may be recognized in time and the adverse consequences prevented. 0 
WG(2)1335E 
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To ANNEX I: 
Amendment No,., 7: 
Sub-programme 2, in the paragraph ;Enzyme engineering 8 ~ add to the 1st indent: 
1
ecce for industrial and medical applications •• .,es 
Amendment No .. 8: 
In the paragraph ~Genetic engineering' add the following indent: 
- Production of vaccines, proteins and hormones for human medicine 
Amendment No., 9: 
In the paragraph 'technology of cells and tissues cultured in vitro' delete 
the words 'from a socio-economic point of view 0 • 
Amendment No. 10 
To Action II: in the eighth indent insert the following: 
m ~""fi on the nature, potential and risks of biotechnology 
Ca SUGGESTED AMENDMENTS TO THE MOTION FOR A RESOLUTION 
Amendment No. 11: 
Add the following points to the motion for a resolution: 
calls on the Commission to harmonize programme sections 2.2.2.4®, 2.2.2.5. 
and 2~4 of the biotechnology research programme with Section 2b of the 
COST research action on the effects of processing and marketing on the 
quality and nutritional value of foodstuffs and in particular to 
investigate in the context of the biotechnology research action programme 
the toxicological aspects of which no account was taken in the research 
action, 
calls on the Commission to make proposals as soon as possible in the 
context of Actic.1 IV for common safety precautions, particularly for DNS 
recombinations. 
D., CONCLUSION 
The Committee on the Environmentp Public Health and Consumer Protection 
requests the committee responsible to adopt the above amendments which seek to 
clarify the points made in the introductionu Subject to the adoption of these 
amendments, the committee fully approves the proposals submitted. 
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OPINION OF THE COMMITTEE ON LEGAL AFFAIRS AND CITIZENS 9 RIGHTS 
Letter from the chairman of the committee to Mr PONIATOWSKI, chairman of the 
Committee on Energy, Research and Technology 
Subject: Proposal for a Council Decision adopting a multiannual research 
action programme of the European Economic Community in the fie[d of 
b1otechnology <1985-1989) (Doc. 1-355/84 - COMC845 230 final) 
Dear Mr Poniatowski, 
At its meeting of 29/30 November 1984 in Brussels, the Committee on Legal 
Affairs and Citizens 0 Rights considered the Commission proposal referred to 
above .. 
The Committee on Legal Affairs and Citizens' Rights notes that the Commission 
is proposing to put forward 'general or specific proposals appropriate to 
create a regulatory framework suitable for the development of the activities 
of the bio-industries and for the free circulation of goods produced by bio-
technology0, and that it has already set up a working party to investigate the 
problems associated with intellectural property rights in the biotechnology 
field, especially as regards patents, for which improvements in current 
legislation are planned. 
Given that no firm proposals with regard to the two measures referred to above 
are included in the proposed multiannual programme, the Committee on Legal 
Affairs and Citizens 0 Rights has decided to reserve its position on these two 
measures until formal proposals from the Commission are referred to Parliament. 
It considers, however, that paragraph 9 of the motion for a resolution in 
Mrs Viehoffes draft report (PE 91.447/fina)p on the need to harmonize patent 
law in this field, is just as likely to prejudice the position of Parliament 
and the Commission in a very complex field, particularly as discussions and 
negotiations are to be organized in the near future on the basis of a detailed 
study carried out by the OECDa 
In addition to these comments on the proposed multiannual programme, my 
committee has instructed me to inform you that it intends to draw up an own-
initiative report on the legal (and ethical) problems to which developments in 
biology may give rise; this report may cover some of the aspects referred to 
by the rapporteur in paragraph 2 of her motion for a resolutions 
Yours sincerely, 
Marie-Claude VAYSSADE 
The following were present: Mrs Vayssade, chairman; Mr Evrigenis and Mr 
Gazis, vice-chairmen; Mr Andrewsp Mrs Fontaine, Mr Pordea, Mr Price, Mr 
Tortorap Mr Ulburghs, Mr Wijsenbeek and Mr Zagarim 
30 ·November 1984 
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